1. Secondary Prevention of Macrovascular Events in Type 2 Diabetes: Focus on Dyslipidemia

2. Panelists

3. PPAR-alpha and PPAR-gamma Agonists: Target Systems

4. PPAR-alpha Agonists

5. PPAR-gamma Agonists

6. Genes Regulated by Glitazones

7. Effect of Fibrates on CV Outcomes: A Systematic Review and Meta-Analysis

8. PPAR-gamma Agonists: Effect on Lipids

9. PPAR-gamma Agonists: CV Events

10. Dual PPAR-alpha/gamma Agonists: Expected Targets

11. GALLANT 8: Effect of Tesaglitazar on HbA1c

12. GLAD: Effect of Tesaglitazar on Lipid Measures

13. Tesaglitazar: Effect on Serum Creatinine and Glomerular Filtration

14. Tesaglitazar: Clinical Development Summary

15. Muraglitazar: Effect on HbA1c and Lipid Levels

16. Muraglitazar: Effect on All-Cause Mortality and MACE in Patients With T2D

17. Muraglitazar: Clinical Development Summary

18. PROactive: Heart Failure

19. SYNCHRONY: Effect of Aleglitazar on LDL-C and HDL-C

20. AleNephro: Effect of Aleglitazar on Lipid Levels

21. SYNCHRONY: Effect of Aleglitazar on HbA1c and FPG

22. SYNCHRONY: Effect of Aleglitazar on Markers of Renal Function

23. AleNephro: Objective and Study Design

24. AleNephro: Effect of Aleglitazar on eGFR and SCr in Patients With Renal Impairment

25. AleCardio: Aleglitazar in Patients With T2D and ACS

26. AlePrevent: Aleglitazar in Patients With Stable CVD and Glucose Abnormalities

27. Moderator Summary

28. Abbreviations

29. Abbreviations (cont)

30. References

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)